Plain-English translation of NCT06238921 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination approach for people with advanced triple-negative breast cancer that has spread to the brain. The study combines radiation therapy (focused beams aimed at brain tumors) with two medications: and . Researchers want to see if this combination works better and is safe compared to using alone.
Triple-negative breast cancer is an aggressive form of the disease that doesn't respond to some standard hormone-based treatments, and when it spreads to the brain, it becomes even harder to treat. This trial is exploring whether combining targeted radiation with newer immunotherapy medications can improve outcomes for patients facing this serious diagnosis.
You likely qualify if…
You likely don't qualify if…
You would first receive focused radiation therapy to your brain tumors. One week later, you would begin receiving the two medications by IV infusion—the first medication on specific days (days 1 and 8 of each cycle) and the second medication on day 1 of each cycle. These treatment cycles repeat every 3 weeks, and your doctors will check how you're responding with imaging scans every 9 weeks. The trial involves about 31 participants total.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States